Advisory Board and Editors Translational Medicine
Olorunseun O Ogunwobi
Dr. Ogunwobi obtained a medical degree from the University of Ibadan, Nigeria, a master's degree in biomedicine from the University of Hull, United Kingdom, a master's degree in clinical and translational science from the University of Florida, Gainesville, and a PhD in molecular biology from the University of East Anglia, Norwich, United Kingdom. He was the Founding Director of the Hunter College Center for Cancer Health Disparities Research. He is now the Barnett Rosenberg Professor of Biochemistry and Molecular Biology and Chairperson in the Department of Biochemistry and Molecular Biology at Michigan State University. In addition, he will serve as Co-Director of the forthcoming Center for Cancer Health Equity Research (CCHER) at Michigan State University. He is a translational cancer biologist whose work focuses on molecular mechanisms of progression of solid organ cancers with racial disparities, and on approaches to leverage non-coding RNA biology for potential clinical applications in cancer. His work has been funded by the National Institutes of Health, New York State, Carnegie Corporation of New York, and the National Science Foundation, among others. Dr. Ogunwobi was a Founding Contact Principal Investigator of the Synergistic Partnership for Enhancing Equity in Cancer Health (SPEECH) funded by U54 grants CA221704 and CA221705 from the National Cancer Institute. An author of 74 peer-reviewed journal articles and 3 book chapters, Dr. Ogunwobi has been issued 5 US patents for biotechnology inventions with potential clinical applications in cancer. He is the recipient of the 2022 Hunter College Presidential Award for Excellence in Scholarship or Creative Activity, and selected as a Jefferson Science Fellow by the National Academies of Sciences, Engineering, and Medicine, and as a Fellow of the Academy of Medicine Specialties of Nigeria. He is Co-Founder of UTR Therapeutics, Inc (winner of the 2023 XSeed Award from Deerfield), and NucleoBio, Inc.
Sonia MR Oliveira
Doctor Sonia Oliveira holds a Licenciatura in Biology (pre-Bologna) and a Master in Cellular and Molecular Biology from the University of Aveiro, where she also specialized in medicinal plants, toxicology, murine models, and spermatogenesis. In 2011 she moved to Australia to work in Reproductive Biological Sciences. She later explored the nerve-cancer connection in Cancer, namely in female cancers, and completed her Ph.D. in Human Physiology ( with a significant component in Medical Biochemistry and Neurophysiology) from the University of Newcastle (Australia) in 2018. She then worked with biomimetic systems and nanotechnology in diabetes and stem cells. She explored multiple methods for primary and secondary cell culture, always with a keen interest in histopathology, cell biology, and rare disorders. Participated in >40 event(s). (Co-)Supervised MSc dissertation(s) and final projects for course completion of LSc/BSc. And works mostly in the area(s) of Natural sciences with emphasis on Molecular and Cellular Biology, and Medical and Health Sciences with emphasis on Neurosciences, Cancer, Reproduction, Toxicology, Biotechnology, and Stem cells. Also has collaborations in Microbiology, Biomaterials, and Communication and Information technologies.
Pierpaolo Pani
Dr. Pierpaolo Pani is a Associate Professor within the Department of Physiology and Pharmacology, SAPIENZA, University of Rome. He received a MSc in Experimental Psychology and PhD in Neurophysiolgy (Behavioral and Integrative) at Sapienza University (Rome), and was a post-doc in KULeuven (Laboratory for Neuro- and Psychophysiology).
Dr. Pani's main topics of investigation include Cognitive control, executive functions, goal-oriented behavior and decision making. These topics include behavioral and psychophysiological investigations in humans; behavioral and neuronal dynamics investigations in mammals; characterization of executive functions control in psychiatric conditions.
Anurag N Paranjape
Passionate about understanding the mechanisms governing cancer metastasis with a hope of finding new targetable pathways. Have worked on breast cancer stem cells, EMT, prostate cancer stem cells, breast cancer brain metastasis, and blood-brain barriers.
Kevin Petrie
I obtained my PhD from the Institute of Cancer Research in London spent a further 10 years there as a postdoctoral fellow and Staff Scientist. I am currently a Lecturer in Molecular Biology at the University of Stirling in Scotland. My principal research interest is translational oncology, with a focus on epigenetics.
Rafael Radi
Professor and Chairman of Biochemistry, Facultad de Medicina, Universidad de la República, Uruguay. Discovery Award of the Society for Free Radical Biology and Medicine (SFRBM, 2011), Alexander Von Humboldt Senior Award (2010), National Prize in Science and Technology (2007). Howard Hughes International Research Scholar (2000-2011). Past-President of SFRBM and of the Society for Free Radical Research International. Foreign Associate of the US National Academy of Sciences (2015). Founding Member and current President of the Academia Nacional de Ciencias del Uruguay.
Michael A. Rogawski
Professor, Department of Neurology, School of Medicine; Pharmacology and Toxicology Graduate Group; Center for Neuroscience; University of California, Davis. Past president, American Society for Experimental NeuroTherapeutics. Academic editor of 9 journals. Co-founder of Epilepsy Currents, the journal of the American Epilepsy Society.
I received a B.A. (biophysics) from Amherst College, and M.D. and Ph.D. (pharmacology) degrees from Yale University. I was a resident, fellow and assistant professor in the Department of Neurology at the Johns Hopkins University School of Medicine. For over 20 years, I was a senior investigator and chief of the Epilepsy Research Section at the National Institute of Neurological Disorders and Stroke. My research interests involve ion channel pharmacology and neurological therapeutics, including antiepileptic drugs and other epilepsy treatment approaches.
Teresa M Seccia
Associate Professor in Internal Medicine, Dept. Medicine, University of Padova, Italy.
International PhD Degree in 'Arterial Hypertension and Vascular Biology'.
Field of interest: Clinical and translational research in high blood pressure and cardiovascular diseases.
Mirela Sedic
Dr Mirela Sedic (born Bauman) is Principal Scientist at the Institute for Anthropological Research Zagreb. She has authored over 50 scientific publications in peer-reviewed journals including high-impact journals such as BBA Molecular Basis of Disease, Molecular Cancer, The Journal of Pathology, Molecular Cancer Therapeutics, Journal of Medicinal Chemistry, European Journal of Medicinal Chemistry and Cancer Treatment Reviews.
She was the co-PI of international collaborative project with Functional Genomics Center Zurich in Switzerland (PRIME-XS-0000184 Proteomic profiling of retinal proteins from rat model of age-related macular degeneration 2012-2014) and the PI of the University of Rijeka grant “Screening and biological evaluation of acid ceramidase and sphingosine kinase inhibitors as a new class of anti-tumour agents” (2014 – 2017). She is currently the PI of the project funded by the Croatian Science Foundation “Dissecting the mechanisms of therapy resistance in BRAF-mutant colon cancer using an integrated –omics approach” (2019 – 2023) and the PI of the University of Rijeka research grant “Molecular features associated with BRAFV600E-mutated versus wild type BRAF colorectal cancer” (2019-2022). She is also the PI of the project No. 3238 - EPIC-XS 012: “Proteomic analysis of acquired resistance to vemurafenib in BRAF V600E–mutant colon cancer cells” (2019 - 2022) in collaboration with the Functional Genomics Center Zurich in Switzerland.
Yuan Shang
Dr. Yuan Shang works on Alzheimer's Disease (AD) at the University of Arizona. He combines any potential methods and data to search potential therapeutic opportunities for AD. He is an expert on omics data analysis, multi-omics integrations, network-based pattern recognition, and machine learning-based biomarker discoveries.
Nicholas Syn
Nicholas Syn, MBBS, is a researcher at Yong Loo Lin School of Medicine, National University of Singapore. His research interests are in general surgery, transplant surgery, and translational oncology. He has published over 109 PubMed-indexed articles in these areas, and has a H-index of 19 (updated as of 16th Apr, 2021).
Abhishek Tyagi
I have been working on the molecular mechanisms of cancer progression and metastasis for the last ten years, identifying signaling pathways that promote cancer progression using various in vitro and in vivo models. During this time, I have published 30 articles with more than 2000 citations, and 12 papers have been cited as being in the top 10% of the field. They have mostly appeared in high-impact journals such as Sci. Adv., Nat. Comm., J. Exp. Med., Clinical Can. Res., Oncogene, Cancer Res., Cancer Letters. My research is primarily concerned with mechanistic and translational studies of tumor-initiating cells, the microenvironment, and non-coding RNAs in the context of cancer progression and metastasis. My long-term research goal is to conduct basic and translational research to elucidate the underlying mechanism(s) driving cancer metastasis and identify therapeutic targets, especially for highly aggressive metastatic cancers. In addition, I also serve on the editorial boards of three cancer-related journals. Before joining the department of Cancer Biology at Wake Forest University School of Medicine, I was a senior research officer (SRO) at the Delhi State Cancer Institute, India (Govt. of India).
I am or have been...
1. A self-motivated, goal-oriented cellular/molecular biologist with over 7 years of experience in oncology.
2. Substantial experience in designing and executing well-controlled in vitro and in vivo assays for preclinical drug discovery, synthetic lethal screening, biomarker identification, target validation, immunogenicity, and toxicity assessment
3. Capable of investigating signaling pathways with a variety of molecular and genetic tools
4. Enthusiastic team worker and expert in forming strategic collaborations